Publications by authors named "Yohei Kubota"
Article Synopsis
- This study analyzes real-world data from a comprehensive genomic profiling (CGP) of 1,364 patients with advanced small intestine cancer, focusing on identifying clinically relevant genetic alterations across different patient subgroups based on age and molecular characteristics.
- Key findings reveal that patients under 40 have a significantly lower rate of certain mutations compared to older patients, and 22.3% of the cohort had mutations that could be targeted by existing therapies.
- The results contribute to a better understanding of the genetic landscape of small intestine cancer, which may help guide future treatment strategies.
Background: Panel-based comprehensive genomic profiling is used in clinical practice worldwide; however, large real-world datasets of patients with advanced gastric cancer are not well known.
Objective: We investigated what differences exist in clinically relevant alterations for molecularly defined or age-stratified subgroups.
Methods: This was a collaborative biomarker study of a real-world dataset from comprehensive genomic profiling testing (Foundation Medicine, Inc.
Background: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC).
Material And Methods: Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts.
Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Ther Adv Med Oncol
January 2024
Claudins (CLDNs) are a family of major membrane proteins that form components of tight junctions. In normal tissues, CLDNs seal the intercellular space in the epithelial sheets to regulate tissue permeability, paracellular transport, and signal transduction. Claudin18.
View Article and Find Full Text PDFRecently, immune checkpoint inhibitor (ICI), such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies, has provided clinical benefits in various cancer types including advanced gastric cancer (AGC). Nivolumab, a monoclonal anti-PD-1 antibody, firstly showed an improvement in the overall survival (OS) in patients with AGC in the ATTRACTION-2 trial. Recently, chemotherapy plus nivolumab, as a first-line treatment for AGC, showed both OS and progression-free survival (PFS) benefits in patients with PD-L1 combined positive score (CPS) ≥5 in the global CheckMate-649 trial, and demonstrated PFS benefit irrespective of CPS status in the Asian ATTRACTION-4 trial.
View Article and Find Full Text PDFArticle Synopsis
- The study compares patient outcomes and characteristics between those enrolled in randomized trials for immune checkpoint inhibitors (ICI) plus chemotherapy for advanced gastric cancer and those treated under standard clinical practice.
- The control group from trials showed significantly better performance status and longer times to starting chemotherapy compared to the practice group.
- Findings indicated that patients in the trial setting experienced longer median overall survival than those in clinical practice, suggesting that trial participants may have better prognostic factors influencing their outcomes.
Purpose: We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint inhibitors.
Experimental Design: Patients with AGC who received systemic chemotherapy from October 2015 to July 2018 with available molecular features were analyzed. We investigated the efficacy of standard first- (fluoropyrimidine + platinum ± trastuzumab) and second-line (taxanes ± ramucirumab) chemotherapy, and subsequent anti-PD-1 therapy in patients with four molecular subtypes: MMR-D (mismatch repair deficient), EBV, HER2, and all negative.
Aim: The aim of this study is to clarify the value of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA -M2BP) for predicting hepatocellular carcinoma (HCC) in chronic hepatitis C patients who achieved sustained virologic response (SVR) by therapy with interferon-free, direct-acting antivirals (DAAs).
Methods: This is a retrospective cohort study that included 567 patients who underwent antiviral therapy with an interferon-free DAA regimen and achieved SVR. Serum WFA -M2BP was measured after SVR.
When elderly patients are prescribed many different medications, the risk for developing serious adverse events should be kept in mind. One of these adverse events is agranulocytosis, which, although rare, can be life-threatening if left untreated. The majority of agranulocytosis cases are caused by drugs, including antibiotics.
View Article and Find Full Text PDFArticle Synopsis
- - The study analyzed 224 patients with intermediate-stage hepatocellular carcinoma who received transarterial chemoembolization (TACE), aiming to understand how subclassification using the up-to-seven criteria affects their clinical outcomes and liver function.
- - Results showed a median survival of 35.8 months, with 25% of patients experiencing tumor downstaging to meet the Milan criteria, which was linked to significantly longer survival.
- - The up-to-seven criteria were found to be a useful prognostic tool for predicting tumor recurrence and liver function deterioration in these patients, alongside other clinical factors like serum albumin and bilirubin levels.